Figure 4From: Dynamic tumor modeling of the dose–response relationship for everolimus in metastatic renal cell carcinoma using data from the phase 3 RECORD-1 trial Visual predictive check (VPC) of 10,000 simulated patients (A) on placebo before their switch to everolimus, and (B) on everolimus who received continuous 10 mg dosing throughout the trial. CI, confidence interval; pctile, percentile; Sim, simulated; SLD, sum of the longest tumor diameters.Back to article page